Copyright
©The Author(s) 2023.
World J Gastroenterol. May 28, 2023; 29(20): 3168-3184
Published online May 28, 2023. doi: 10.3748/wjg.v29.i20.3168
Published online May 28, 2023. doi: 10.3748/wjg.v29.i20.3168
Table 1 Demographics and clinical characteristics of hepatocellular carcinoma patients
Variables | Training cohort (n = 120) | Validation cohort (n = 30) | Overall cohort (n = 150) | P value | |
Patient factors | |||||
Age [yr, mean (SD)] | 51.5 (12.1) | 54.4 (10.9) | 52.1 (11.9) | 0.419 | |
Sex, male/female | 104/16 (86.7%/13.3%) | 24/6 (80.0%/20.0%) | 128/22 (85.3%/14.7%) | 0.526 | |
Etiology, HBV/other | 109/11 (90.8%/9.2%) | 25/5 (83.3%/16.7%) | 134/16 (89.3%/10.7%) | 0.39 | |
Ascites, yes/no | 20/100 (16.7%/83.3%) | 7/23 (23.3%/76.7%) | 27/123 (18.0%/82.0%) | 0.559 | |
Child-Pugh, A/B | 114/6 (95.0%/5.0%) | 29/1 (96.7%/3.3%) | 143/7 (95.3%/4.7%) | 1 | |
Laboratory parameters | |||||
AFP (ng/mL, ≤ 200/> 200) | 68/52 (56.7%/43.3%) | 15/15 (50.0%/50.0%) | 83/67 (55.3%/44.7%) | 0.652 | |
HGB [g/dL, median (min, max)] | 139 (72, 838) | 139 (100, 162) | 139 (72, 838) | 0.714 | |
PLT [count, × 109/L, median (min, max)] | 197 (70, 950) | 189 (97, 370) | 192 (70, 950) | 0.873 | |
AST [U/L, median (min, max)] | 36.0 (2, 471) | 33.0 (16, 251) | 35.0 (2, 471) | 0.925 | |
ALT [U/L, median (min, max)] | 34.0 (9, 423) | 29.0 (12, 329) | 34.0 (9, 423) | 0.541 | |
ALB (g/L, ≤ 35/> 35) | 18/102 (15.0%/85.0%) | 2/28 (6.7%/93.3%) | 20/130 (13.3%/86.7%) | 0.368 | |
TB [μmol/L, median (min, max)] | 12.5 (3.2, 28.2) | 12.9 (4.3, 30.9) | 12.7 (3.2, 30.9) | 0.996 | |
GGT [U/L, median (min, max)] | 59.5 (15, 435) | 57.0 (22, 375) | 59.0 (15, 435) | 0.987 | |
BUN (mmol/L, ≤ 6.7/> 6.7( | 109/11 (90.8%/9.2%) | 26/4 (86.7%/13.3%) | 135/15 (90.0%/10.0%) | 0.734 | |
Creatinine [μmol/L, median (min, max)] | 77.6 (23, 218) | 74.0 (43, 110) | 77.0 (23, 218) | 0.263 | |
UA [μmol/L, median (min, max)] | 335 (172, 680) | 329 (143, 572) | 334 (143, 680) | 0.899 | |
PT [s, median (min, max)] | 13.6 (11.1, 16.5) | 13.6 (12.1, 15.6) | 13.6 (11.1, 16.5) | 0.212 | |
Tumor factors | |||||
Tumor number (1/2/≥ 3) | 80/22/18 (66.7%/18.3%/15.0%) | 16/7/7 (53.3%//23.3%/23.3%) | 96/29/25 (64.0%/19.3%/16.7%) | ||
Tumor size (cm, ≤ 5/> 5) | 39/81 (32.5%/67.5%) | 11/19 (36.7%/63.3%) | 50/100 (33.3%/66.7%) | 0.829 | |
MVI, yes/no | 55/65 (45.8%/54.2%) | 13/17 (43.3%/56.7%) | 68/82 (45.3%/54.7%) | 1 | |
Tumor capsule, ill-defined/well-defined | 29/91 (24.2%/75.8%) | 11/19 (36.7%/63.3%) | 40/110 (26.7%/73.3%) | 0.249 | |
Satellite nodules, yes/no | 26/94 (21.7%/78.3%) | 10/20 (33.3%/66.7%) | 36/114 (24.0%/76.0%) | 0.272 | |
Surgical factors | |||||
TACE (c-TACE/DEB-TACE) | 79/41 (65.8%/34.2%) | 21/9 (70.0%/30.0%) | 100/50 (66.7%/33.3%) | 0.829 | |
Resection Margin (cm, < 1/≥ 1) | 13/107 (10.8%/89.2%) | 4/26 (13.3%/86.7%) | 17/133 (11.3%/88.7%) | 0.949 | |
Blood transfusion, yes/no | 38/82 (31.7%/68.3%) | 14/16 (46.7%/53.3%) | 52/98 (34.7%/65.3%) | 0.184 | |
Conventional staging system | |||||
AJCC (I/II/III) | 42/20/58 (35.0%/16.7%/48.3%) | 10/4/16 (33.3%/13.3%/53.3%) | 52/24/74 (34.7%/16.0%/49.3%) | 0.889 | |
BCLC (A/B/C) | 31/35/54 (25.8%/29.2%/45.0%) | 10/7/13 (33.3%/23.3%/43.3%) | 41/42/67 (27.3%/28.0%/44.7%) | 0.678 | |
CNLC (I/II/III) | 47/19/54 (39.2%/15.8%/45.0%) | 12/5/13 (40.0%/16.7%/43.3%) | 59/24/67 (39.3%/16.0%/44.7%) | 1 | |
Okuda (I/II/III) | 65/54/1 (54.2%/45.0%/0.8%) | 15/15/0 (50.0%/50.0%/0%) | 80/69/1 (53.3%/46.0%/0.7%) | 0.749 | |
JIS (0/1/2/3/4) | 1/42/55/21/1 (0.8%/35.0%/45.8%/17.5%/0.8%) | 0/10/12/8/0 (0%/33.3%/40.0%/26.7%/0%) | 1/52/67/29/1 (0.7%/34.7%/44.7%/19.3%/0.7%) | 0.716 | |
CLIP (0/1/2/3/4) | 27/28/35/21/9 (22.5%/23.3%/29.2%/17.5%/7.5%) | 7/7/9/4/3 (23.3%/23.3%/30.0%/13.3%/10.0%) | 34/35/44/25/12 (22.7%/23.3%/29.3%/16.7%/8.0%) | 0.962 | |
Inflammation index | |||||
GPR (≤ 0.38/> 0.38) | 66/54 (55.0%/45.0%) | 18/12 (60.0%/40.0%) | 84/66 (56.0%/44.0%) | 0.773 | |
LMR (≤ 2.39/> 2.39) | 26/94 (21.7%/78.3%) | 6/24 (20.0%/80.0%) | 32/118 (21.3%/78.7%) | 1 | |
NLR (≤ 2.00/> 2.00) | 60/60 (50.0%/50.0%) | 16/14 (53.3%/46.7%) | 76/74 (50.7%/49.3%) | 0.903 | |
PLR (≤ 84.38/> 84.38) | 35/85 (29.2%/70.8%) | 13/17 (43.3%/56.7%) | 48/102 (32.0%/68.0%) | 0.204 | |
NrLR (≤ 644.61/> 644.61) | 106/14 (88.3%/11.7%) | 28/2 (93.3%/6.7%) | 134/16 (89.3%/10.7%) | 0.643 | |
APRI (≤ 0.30/> 0.30) | 91/29 (75.8%/24.2%) | 20/10 (66.7%/33.3%) | 111/39 (74.0%/26.0%) | 0.429 | |
ANRI (≤ 4.76/> 4.76) | 10/110 (8.3%/91.7%) | 4/26 (13.3%/86.7%) | 14/136 (9.3%/90.7%) | 0.623 | |
ALRI (≤ 41.96/> 41.96) | 97/23 (80.8%/19.2%) | 24/6 (80.0%/20.0%) | 121/29 (80.7%/19.3%) | 1 | |
PNI (≤ 52.62/> 52.62) | 93/27 (77.5%/22.5%) | 22/8 (73.3%/26.7%) | 115/35 (76.7%/23.3%) | 0.809 | |
SII (≤ 336.22/> 336.22) | 48/72 (40.0%/60.0%) | 13/17 (43.3%/56.7%) | 61/89 (40.7%/59.3%) | 0.901 |
- Citation: Wu JL, Luo JY, Jiang ZB, Huang SB, Chen GR, Ran HY, Liang QY, Huang MS, Lai LS, Chen JW. Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy. World J Gastroenterol 2023; 29(20): 3168-3184
- URL: https://www.wjgnet.com/1007-9327/full/v29/i20/3168.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i20.3168